The biotech sector in Germany: Resilient despite challenging conditions

Germany’s biotech sector continues to demonstrate remarkable resilience. Despite challenging framework conditions, many companies continue to invest in R&D, expand their teams, and look cautiously optimistic toward 2026. For early-stage biotech startups in particular, this raises an important question: how can strong research and technological depth be reliably translated into growth, partnerships, and real-world applications?

At the same time, the BIO Deutschland 2025/2026 trend survey highlights a clear tension: while many companies remain willing to invest in innovation, confidence in the broader framework conditions is significantly lower. Only 15% currently rate the political environment as supportive, while 30% consider it negative. This contrast is telling. It suggests that progress in biotechnology is currently driven less by favourable conditions and more by the sector’s own persistence and long-term orientation.

The outlook for 2026 remains cautiously constructive: the innovation pipeline is strong, but the sector’s full potential will depend on whether framework conditions evolve at the same pace.

For early-stage biotech startups, this poses a central challenge: how can scientific excellence and technological depth be reliably translated into growth, partnerships, and concrete applications?

Against this backdrop, support structures within the innovation ecosystem play a particularly important role. Incubators, networks, and collaborative formats can help bridge the gap between research and application and facilitate the translation of innovation into market-ready solutions.

This is precisely where the Hightech Incubator BioIntelligence operates within the Lower Saxony ecosystem. Research-driven founding teams are supported in translating their scientific potential into viable business models, industry collaborations, and investor readiness. As part of the regional innovation infrastructure, BioIntelligence contributes to closing the gap between excellent biotech research and scalable applications, helping to ensure that Germany’s strong innovation pipeline also reaches the market.

Link to the report: Trends in the German biotechnology sector in 2026